Solesta (Q-Med AB) for treatment of fecal incontinence
Record ID 32014000403
English
Authors' recommendations:
Fecal incontinence (FI) is the loss of control of the bowels resulting in the involuntary loss of liquid or solid feces. The overall prevalence of FI ranges from 1% to 7% in otherwise healthy individuals. It affects nearly 18 million community-dwelling adults in the United States. FI has a negative impact on the activities of daily living and quality of life. Current treatments for FI range from conservative measures aimed at reducing symptoms (e.g., biofeedback, dietary modification, pelvic floor muscle training, and/or pharmacotherapy) to surgical interventions aimed at correcting anal sphincter or pelvic floor abnormalities.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=14564
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Fecal Incontinence
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2013 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.